Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REGN5381 in Heart Failure Patients With Elevated Pulmonary Capillary Wedge Pressure
NCT05353166Phase 2Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Jun 2022
- Primary completion
- Jun 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of REGN5381 in heart failure (HF), sponsored by Regeneron Pharmaceuticals. Started Jun 2022; status: completed.
02
Drugs
REGN5381
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT05353166.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05353166.